Goebell P, Raina R, Chen S, Rege S, Shah R, Grossman JP, Waldeck AR (2024)
Publication Type: Journal article
Publication year: 2024
Book Volume: 20
Pages Range: 903-918
Journal Issue: 14
Aim: To characterize real-world patients with metastatic hormone-sensitive prostate cancer (mHSPC) and treating physicians and evaluate treatment trends and baseline concordance versus guidelines internationally. Materials & methods: Retrospective, cross-sectional data from the Ipsos Global Oncology Monitor database 2018-2020 were used for descriptive analysis of mHSPC patients, treating physicians and treatment utilization. Results: Among the 6198 mHSPC patients from five countries, the most common treatment was either androgen deprivation therapy (ADT) monotherapy or first-generation androgen receptor inhibitor + ADT. Second-generation androgen receptor inhibitor use was only initiating but increasing over the study period. Conclusion: Despite contemporaneous guidelines recommending treatment intensification of ADT in combination with novel antihormonals or docetaxel, 76.1% of reported mHSPC patients received non-guideline-concordant care.
APA:
Goebell, P., Raina, R., Chen, S., Rege, S., Shah, R., Grossman, J.P., & Waldeck, A.R. (2024). Real-world treatment of metastatic hormone-sensitive prostate cancer in the USA, Europe and Asia. Future Oncology, 20(14), 903-918. https://doi.org/10.2217/fon-2023-0814
MLA:
Goebell, Peter, et al. "Real-world treatment of metastatic hormone-sensitive prostate cancer in the USA, Europe and Asia." Future Oncology 20.14 (2024): 903-918.
BibTeX: Download